Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group
Antonio Bertolotto(Neuroscience Institute), Simona Malucchi(Ospedale San Luigi Gonzaga), Lucia Moiola(Vita-Salute San Raffaele University), Maria Giovanna Marrosu(University of Cagliari), María Trojano(University of Bari Aldo Moro), Luigi Grimaldi(Fondazione Istituto G. Giglio di Cefalù), Alessandra Lugaresi(Istituto delle Scienze Neurologiche di Bologna), Ruggero Capra(Presidio Ospedaliero), Maria Pia Amato(University of Florence), Chiara Mancinelli(Sapienza University of Rome), Luisa Imberti(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Elisabetta Capello(Ospedale Policlinico San Martino), Damiano Paolicelli(University of Bari Aldo Moro), Luigina Musu(ATS Sardegna (Italy)), Francesco Patti(University of Catania), Marco Capobianco(Ospedale San Luigi Gonzaga), Silvia Rossi, Silvia Romano, Carlo Pozzilli(Sapienza University of Rome), Antonio Gallo(University of Campania "Luigi Vanvitelli"), Marco Salvetti(Don Carlo Gnocchi Foundation), Enrico Montanari(University of Ferrara), Maria di Ioia(Associazione Italiana Sclerosi Multipla), Maria Rosaria Tola(University of Ferrara), Diego Centonze(University of Rome Tor Vergata), Gioachino Tedeschi(University of Campania "Luigi Vanvitelli"), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla)
Cited by 2
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Multiple Sclerosis Severity Score
|Neurology|2005|959